- Home
- RNAZ
as 11-15-2024 11:39am EST
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 8.3M | IPO Year: | 2021 |
| Target Price: | $3.00 | AVG Volume (30 days): | 606.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.22 - $18.68 | Next Earning Date: | 11-26-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 100.00% |
Latest TransCode Therapeutics Inc. News
RNAZ Breaking Stock News: Dive into RNAZ Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
TransCode Therapeutics Open Letter to Shareholders
GlobeNewswire
10 days ago
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
GlobeNewswire
23 days ago
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
GlobeNewswire
a month ago
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
GlobeNewswire
2 months ago
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
GlobeNewswire
2 months ago
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
GlobeNewswire
2 months ago
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
GlobeNewswire
3 months ago
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
Compare RNAZ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNAZ TransCode Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.